• CnPharm cut its Hyundai Bioscience stake to 11,373,439 shares from 11,546,001 as of Oct. 13.
• Ownership fell to 11.79% from 11.96%.
• Voting rights dropped to 9,574,235 shares, or 9.92%, from 9,746,797 shares, or 10.10%.
• Change driven by an exchange right exercise on exchangeable bonds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyundai Bioscience Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261013000241), on October 13, 2026, and is solely responsible for the information contained therein.